소아에서 치료 불응성 마이코플라스마 폐렴의 위험 인자에 대한 임상적 분석
Clinical analysis of risk factors in refractory mycoplasma pneumonia in children
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Refractory Mycoplasma pneumonia (RMP) has been increasing not only in Korea but worldwide. We investigated the incidence of M. pneumonia resistant to macrolides and risk factors for RMP. Methods: From October 2015 to May 2016, 62 pediatric patients who were admitted due to pneumonia diagnosed on the basis of chest x-ray with respiratory symptoms and positive for M. pneumoniae in polymerase chain reaction with no evidence of other bacterial or viral infections were included. Sequence analysis of the 23S rRNA gene in M. pneumoniae was performed to identify macrolide resistance. Patients with congenital anomalies, history of pulmonary disease, and unclear information on antibiotic use were excluded. Results: Mutations in the 23S rRNA gene were detected in 50 of 62 patients (80.6%). Risk factors were analyzed in only 45 patients. The RMP group consisted of 26 patients (57.8%) who had fever lasting more than 5 days and deteriorating chest x-ray findings. The lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels were significantly higher in the RMP group than in the non-RMP group (LDH: 300±79 U/L vs. 469±206 U/L, CRP: 4.9±4.3 mg/dL vs. 2.5±1.7 mg/dL; P=0.04 vs. P=0.026). In univariate analysis, the RMP group was significantly associated with 23S rRNA gene mutation, lobar pneumonia, and pleural effusion (odds ration [OR]: 10.8, 4.1, 5.3; P=0.004, P=0.036, P=0.046). The presence of macrolide resistance was found to be only a significant risk factor in logistic regression (OR; 8.827; 95% confidence interval, 1.376–56.622; P=0.022). Conclusion: Macrolide resistance was a significant risk factor in patients with RMP and identification of macrolide resistance might be helpful in predicting RMP and establishing target therapy for RMP.
Abstract
Purpose: Refractory Mycoplasma pneumonia (RMP) has been increasing not only in Korea but worldwide. We investigated the incidence of M. pneumonia resistant to macrolides and risk factors for RMP. Methods: From October 2015 to May 2016, 62 pediatric patients who were admitted due to pneumonia diagnosed on the basis of chest x-ray with respiratory symptoms and positive for M. pneumoniae in polymerase chain reaction with no evidence of other bacterial or viral infections were included. Sequence analysis of the 23S rRNA gene in M. pneumoniae was performed to identify macrolide resistance. Patients with congenital anomalies, history of pulmonary disease, and unclear information on antibiotic use were excluded. Results: Mutations in the 23S rRNA gene were detected in 50 of 62 patients (80.6%). Risk factors were analyzed in only 45 patients. The RMP group consisted of 26 patients (57.8%) who had fever lasting more than 5 days and deteriorating chest x-ray findings. The lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels were significantly higher in the RMP group than in the non-RMP group (LDH: 300±79 U/L vs. 469±206 U/L, CRP: 4.9±4.3 mg/dL vs. 2.5±1.7 mg/dL; P=0.04 vs. P=0.026). In univariate analysis, the RMP group was significantly associated with 23S rRNA gene mutation, lobar pneumonia, and pleural effusion (odds ration [OR]: 10.8, 4.1, 5.3; P=0.004, P=0.036, P=0.046). The presence of macrolide resistance was found to be only a significant risk factor in logistic regression (OR; 8.827; 95% confidence interval, 1.376–56.622; P=0.022). Conclusion: Macrolide resistance was a significant risk factor in patients with RMP and identification of macrolide resistance might be helpful in predicting RMP and establishing target therapy for RMP.
참고문헌 (20)
- 김은경, "Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years", Clinical and Experimental Pediatrics, 58(5), pp.172~177 (2015), 대한소아청소년과학회
- 김진우, "국내소아에서 발생한 마이코플라스마 폐렴 메타분석", Clinical and Experimental Pediatrics, 52(3), pp.315~323 (2009), 대한소아청소년과학회
- 신정은, "Increased risk of refractory Mycoplasma pneumoniae pneumonia in children with atopic sensitization and asthma", Clinical and Experimental Pediatrics, 57(6), pp.271~277 (2014), 대한소아청소년과학회
- 유선영, "Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children", Allergy, Asthma & Immunology Research, 6(1), pp.22~26 (2014), 대한천식알레르기학회
- Shah SS, "Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with Mycoplasma pneumoniae pneumonia", J Hosp Med, 7, pp.311~317 (2012)[DOI]
- Kawai Y, "Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients", Respirology, 17, pp.354~362 (2012)[DOI]
- Wang M, "Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children", Int J Infect Dis, 29, pp.18~23 (2014)[DOI]
- Zhang Y, "The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children", PLoS One, 11, pp.e0156465~ (2016)[DOI]
- Principi N, "Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection", J Antimicrob Chemother, 68, pp.506~511 (2013)[DOI]
- Xin D, "Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China", Antimicrob Agents Chemother, 53, pp.2158~2159 (2009)[DOI]
- Hong KB, "Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011", Emerg Infect Dis, 19, pp.1281~1284 (2013)[DOI]
- 이은, "Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children", Clinical and Experimental Pediatrics, 60(5), pp.151~157 (2017), 대한소아청소년과학회
- Cheong KN, "Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure", J Microbiol Immunol Infect, 49, pp.127~130 (2016)[DOI]
- Lu A, "Lactate dehydrogenase as a biomarker for prediction of refractory Mycoplasma pneumoniae pneumonia in children", Respir Care, 60, pp.1469~1475 (2015)[DOI]
- Matsuoka M, "Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan", Antimicrob Agents Chemother, 48, pp.4624~4630 (2004)[DOI]
- 오지은, "Mycoplasma pneumoniae의 macrolide 내성과 연관된 유전자 변이의 검출", Clinical and Experimental Pediatrics, 53(2), pp.178~183 (2010), 대한소아청소년과학회
- 김종현, "Macrolide Resistance and Its Impacts on M. Pneumoniae Pneumonia in Children: Comparison of Two Recent Epidemics in Korea", Allergy, Asthma & Immunology Research, 9(4), pp.340~346 (2017), 대한천식알레르기학회
- 유진호, "마크로라이드 내성 마이코플라즈마 폐렴이 우리에게 안긴 숙제는?", Allergy Asthma & Respiratory Disease, 5(1), pp.1~2 (2017), 대한 소아알레르기 호흡기학회[DOI]
- Morozumi M, "Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae", Int J Antimicrob Agents, 50, pp.255~257 (2017)[DOI]
- Shan LS, "Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children", World J Pediatr, 13, pp.321~327 (2017)[DOI]